Edwards Lifesciences Boosted After Victory and 2 Stock Analyses to Track

BG Medicine, Inc. (NASDAQ:BGMD) target has been lowered by Ladenburg after its announcement that it intends to transition to a marketing-oriented business model and hire a sales team to sell CardioSCORE. The firm believes that this move is likely to provide the company with greater control over CardioSCOPE, but it also believes that the transition creates more balance sheet risk and has to possibility of necessitating the introduction of more partners. The firm keeps its Buy rating on the stock.

Humana Inc. (NYSE:HUM) was downgraded by Bank of America Merrill Lynch on November 7.

Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.

Edwards Lifesciences Corp. (NYSE:EW): According to Wells Fargo, it perceives today’s appeals court ruling as a significant legal victory for Edwards Lifesciences, noting this is the third favorable court ruling for Edwards in its litigation with Medtronic’s (NYSE:MDT) CoreValve. The firm predicts the upside to Edwards Lifesciences from the litigation may total nearly $486 million after tax, or $4.11 per share. The firm still believes that both companies will negotiate a settlement allowing Medtronic to enter the U.S. market when CoreValve is approved towards the end of 2014. The firm gives an Outperform rating on the stock.

Don’t Miss: Is Nielsen Failing TV Networks?